Form 10-Q · Quarterly report
Ingersoll Rand 10-Q, filed Jul 31, 2026
- Filed
- CIK
- 0001699150
- Accession no.
- 0001628280-26-051415
Summary
Ingersoll Rand reported second-quarter 2026 revenues of $2.05 billion, an 8.5% increase from a year earlier, and net income attributable to the company of $256.8 million versus a year-earlier loss, while citing tariff and macroeconomic uncertainty.
Key points
- Second-quarter 2026 revenues rose to $2,048.8 million from $1,887.9 million in the same period of 2025.
- Net income attributable to Ingersoll Rand was $256.8 million in Q2 2026, compared with a net loss of $115.3 million a year earlier.
- Ingersoll Rand said 2026 has been marked by uncertainty over inflation, elevated interest rates, potential U.S. trade policy shifts and new tariffs, and geopolitical instability from the conflicts in Ukraine and the Middle East.
- The U.S. Supreme Court ruled in February 2026 that tariffs imposed under IEEPA on goods imported into the United States were unauthorized, and U.S. Customs and Border Protection launched a refund-request platform effective April 20, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION Overview Our Company Ingersoll Rand is a global market leader with a broad flow creation and industrial product portfolio across air, gas, powder, and liquid handling applications, providing services and solutions to increase industrial and life science productivity, efficiency, and sustainability. We manufacture one of the broadest and most complete ranges of compressor, pump, vacuum and blower products in our markets, which, when combined with our global geographic footprint and application expertise, allows us to provide differentiated product and service offerings to our customers. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.